Eligibility for Cardiovascular Risk Reduction Therapy in the U.S. Based on SELECT Trial Criteria: Insights from the National Health and Nutrition Examination Survey

Waqas SA, Sohail MU, Saad M, Minhas AMK, Greene SJ, Fudim M, Fonarow GC, Abramov D, Khan MS, Ahmed R. Efficacy of GLP-1 Receptor Agonists[...]

Liu O, Soo S, Bloom M, Alvarez-Cardona J, Katz JN, Cheng RK, Yang EH, Leiva O. Outcomes of Patients with Cancer Admitted with Heart Failure-Associated[...]

Marcus GM, Tung R, Gerstenfeld EP, Hue TF, Lin F, Cheng J, Weiss JP, Tzou WS, Hsia H, Ehdaie A, Cooper DH, Bunch TJ, Arkles[...]